Publications
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.
2010
Eur Respir J
Solovic I, Sester M, Gomez-Reino JJ, et al.
DOI:
10.1183/09031936.00028510
Tuberculosis contact investigation in low prevalence countries: a European consensus.
2010
Eur Respir J
Erkens CGM, Kamphorst M, Abubakar I, et al.
DOI:
10.1183/09031936.00201609
Comparison of interferon-gamma release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study.
2010
Arch Dis Child
Bamford ARJ, Crook AM, Clark JE, et al.
DOI:
10.1136/adc.2009.169805
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
2009
J Antimicrob Chemother
Sotgiu G, Lange C, Richardson MD, et al.
DOI:
10.1093/jac/dkp265
Epidemiology and clinical management of XDR-TB: a systematic review by TBNET.
2009
Eur Respir J
Sotgiu G, Ferrara G, Matteelli A, et al.
DOI:
10.1183/09031936.00168008
Consensus not yet reached on key drugs for extensively drug-resistant tuberculosis treatment.
2009
Clin Infect Dis
Migliori GB, Sotgiu G, D’Arcy Richardson M, et al.
DOI:
10.1086/600060
Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
2009
Clin Chest Med
Migliori GB, D’Arcy Richardson M, Sotgiu G, et al.
DOI:
10.1016/j.ccm.2009.08.015
MDR-TB and XDR-TB: drug resistance and treatment outcomes.
2009
Eur Respir J
Migliori GB, Sotgiu G, D’Arcy Richardson M, et al.
DOI:
10.1183/09031936.00059409
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
2009
Eur Respir J
Migliori GB, Eker B, Richardson MD, et al.
DOI:
10.1183/09031936.00009509
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.
2009
Eur Respir J
Mack U, Migliori GB, Sester M, et al.
DOI:
10.1183/09031936.00120908
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study.
2009
Am J Respir Crit Care Med
Jafari C, Thijsen S, Sotgiu G, et al.
DOI:
10.1164/rccm.200904-0557OC
Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis.
2008
Eur Respir J
Ruhwald M, Bodmer T, Maier C, et al.
DOI:
10.1183/09031936.00055508
Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
2008
Clin Infect Dis
Migliori GB, Lange C, Girardi E, et al.
DOI:
10.1086/528875
Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?
2008
Eur Respir J
Migliori GB, Lange C, Girardi E, et al.
DOI:
10.1183/09031936.00159807
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases.
2008
Eur Respir J
Migliori GB, Lange C, Centis R, et al.
DOI:
10.1183/09031936.00028708